Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight

globenewswire.com
BNTX Mentioned as a key RNA therapeutics company, but no specific sentiment or performance data provided in the article. MRNA Mentioned as a key RNA therapeutics and mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. DVAX Mentioned as a key RNA therapeutics company, but no specific sentiment or performance data provided in the article. ALNY Mentioned as a key RNA therapeutics and mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. BIIB Mentioned as a key RNA therapeutics company, but no specific sentiment or performance data provided in the article. IONS Mentioned as a key RNA therapeutics company, but no specific sentiment or performance data provided in the article. ARCT Mentioned as a key RNA therapeutics company, but no specific sentiment or performance data provided in the article. VRTX Mentioned as a key mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. PFE Mentioned as a key RNA therapeutics and mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. SGMO Mentioned as a key mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. AZN Mentioned as a key mRNA-based vaccines and therapeutics company, but no specific sentiment or performance data provided in the article. CAT Mentioned as a key CDMO company, but no specific sentiment or performance data provided in the article. TMO Mentioned as a key CDMO and viral vector manufacturing company, but no specific sentiment or performance data provided in the article. LH Mentioned as a key CDMO company (Revvity Inc. is a spin-off of LABC), but no specific sentiment or performance data provided in the article.

Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight New York, USA, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight

The global RNAi technology market is witnessing strong growth, driven by the increasing approval and commercialization of RNAi-based therapeutics for rare genetic, metabolic, cardiovascular, and liver diseases. Advancements in RNA delivery technologies, including lipid nanoparticles (LNPs) and GalNAc conjugates, have significantly improved the safety and efficacy of RNAi drugs, accelerating clinical development. Rising investments in biotechnology research, expanding strategic collaborations between pharmaceutical and biotech companies, and growing applications of RNAi in precision medicine and oncology are further supporting market expansion.

DelveInsight’s RNAi Technology Market Insights report provides the current and forecast market analysis, individual leading RNAi technology companies’ market shares, challenges, RNAi technology market drivers, barriers, trends, and key RNAi technology companies in the market.

RNAi Technology Market Summary

To read more about the latest highlights related to the RNAi technology news, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/rnai-technology-market

Key Factors Contributing to the Rise in Growth of the RNAi Technology Market

Get a sneak peek at the RNAi technology market dynamics @ RNAi Technology Market Trends

Regional RNAi Technology Market Insights

North America

Europe

Asia-Pacific

To know more about why North America is leading the market growth in the RNAi technology market, get a snapshot of the RNAi Technology Market Share

Recent Developmental Activities in the RNAi Technology Market

What is RNAi Technology?

RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses the expression of disease-causing genes by targeting messenger RNA (mRNA) before it can be translated into proteins. The process uses small interfering RNA (siRNA) or microRNA (miRNA) molecules that bind to complementary mRNA sequences, triggering their degradation through the RNA-induced silencing complex (RISC). By preventing the production of specific proteins, RNAi technology offers a highly targeted therapeutic strategy for treating diseases driven by abnormal gene expression, including rare genetic disorders, metabolic diseases, infectious diseases, and certain cancers. Its ability to precisely modulate gene activity while minimizing effects on unrelated genes has made RNAi a transformative platform in modern drug development, with several approved therapies and an expanding pipeline of investigational treatments.

RNAi Technology Market Assessment

Which MedTech key players in the RNAi technology market are set to emerge as the trendsetter explore @ RNAi Technology Market Analysis

Table of Contents

Interested in knowing the RNAi technology market share by 2034? Click to get a snapshot of the Top RNAi Technology

Related Reports

RNA Therapeutics Market

RNA Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RNA therapeutics companies such as Pfizer Inc. (BioNTech), Moderna, Dynavax Technologies, Alnylam Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, Novartis, Bausch + Lomb, Gennova Biopharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, Arcturus Therapeutics, Inc., Biogen, NS Pharma, Inc., Eyetech Pharmaceuticals, and others.

mRNA-based Vaccines and Therapeutics Market

mRNA-based Vaccines and Therapeutics Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key mRNA-based vaccines and therapeutics companies such as Vertex Pharmaceuticals Incorporated, ReCode Therapeutics, ModernaTX, Inc., Merck Sharp & Dohme LLC, Remix Therapeutics, Audentes Therapeutics, Pfizer, Sirnaomics, Phoenicis Therapeutics, Astellas Pharma US, Inc., Immorna Biotherapeutics, Inc., ICON plc, Sangamo Therapeutics, 2seventy bio, Hillhurst Biopharmaceuticals, Inc., Silence Therapeutics plc, STORM Therapeutics LTD, BioNTech SE, Agomab Therapeutics NV, Alnylam Pharmaceuticals, Janssen Pharmaceutica N.V., AstraZeneca, Ocugen, Merus N.V., Sanofi, Immunomic Therapeutics, and others.

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key CDMO companies such as Catalent Inc., Thermo Fisher Scientific Inc., The Lubrizol Corporation, Recipharm (EQT), Cambrex Corporation, Merck & Co. Inc., AGC Biologics, Nerpharma S.r.l., Danaher Corporation, EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Revvity Inc., WuXi Biologics, Laboratoire Elaiapharm, and others.

Viral Vector Manufacturing Market

Viral Vector Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key viral vector manufacturing companies such as Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

Viral Vector CDMO Market

Viral Vector CDMO Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key viral vector CDMO companies such as Lonza Group, Thermo Fisher Scientific, Catalent, Oxford Biomedica, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, WuXi AppTec, Merck KGaA, AGC Biologics, Takara Bio, Samsung Biologics, Curia Global, GenScript ProBio, Creative Biogene, VectorBuilder, Aldevron, FinVector, Yposkesi, VGXI, Genezen, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.